Sentences with phrase «ovarian cancers studied»

The researchers found that these immune system pathways were suppressed in a large number of primary tumors — roughly 50 percent of ovarian cancers studied, 40 percent of colorectal cancers and 30 percent of breast cancers.

The highlights included successful US and European ovarian cancer studies that underlined the potential of the company's Parsortix liquid biopsy system

This is the first ovarian cancer study to use a combination of drugs that could be taken orally.

Not exact matches

Several studies have shown a possible correlation between increased height and increased risk of prostate and ovarian cancer.

The products are being studied as treatments for skin cancer, recurrent ovarian cancer and high LDL, or bad cholesterol, that doesn't respond to pills such as Lipitor.

Several observational studies have looked at the link between increased consumption of onions and a reduced risk of certain types of cancers, including stomach, breast, colon, prostate and ovarian.

Studies show that the longer a woman breastfeeds the more she reduces the risk of many illnesses to her child (such as childhood cancers) and risk of illness to herself (lower risk of breast, ovarian, and cervical cancer).

Studies also show that there is a decreased incidence of breast and ovarian cancer and possible decreased risk of osteoporosis.

Limitations in the underlying studies prevent us from modeling the effect of extended lactation on some maternal conditions (eg, ovarian cancer).

Recent studies show that women who breastfeed enjoy decreased risks of breast and ovarian cancer, anemia, and osteoporosis.

Studies show that women who have breastfed experience reduced rates of breast and ovarian cancer later in life.

• According to studies, there is a link between breastfeeding and a lower incidence of several diseases in women, including Type 2 diabetes, ovarian cancer and breast cancer.

Reduced Risk of Some Cancers Studies have found the longer a mom breastfeeds, the more they are protected against breast and ovarian cancer.

Earlier studies have shown that mothers who nurse their babies exhibit lower risk of breast and ovarian cancers.

And studies show that breastfeeding helps lower a woman's risk of breast cancer, high blood pressure, diabetes, and cardiovascular disease, and also may help decrease the risk of uterine and ovarian cancer.

Background: Epidemiologic studies have yielded inconsistent findings between breastfeeding and epithelial ovarian cancer (EOC) risk.

Some studies have shown that breastfeeding reduces a woman's chance of breast and ovarian cancer later in life.

Some studies suggest it may help prevent bone loss later in life and possibly lower the risk of ovarian cancer by delaying the onset of menstruation after pregnancy.

«Nonetheless, the proof of concept studies we have obtained thus far are extremely encouraging, and we are confident that with proper support and efforts we could translate our findings into experimental therapeutics for a variety of solid tumors that are driven by EphA2 overexpression, including breast, lung, prostate, pancreatic, and ovarian cancers,» said Pellecchia, who serves as the founding director of the Center for Molecular and Translational Medicine at UCR.

«Experimental drug combined with standard chemo may shrink treatment - resistant ovarian cancers, animal study shows.»

Based on results of the current study described in a report online June 18 in the journal Cancer Cell, Johns Hopkins researchers say they are planning a phase I clinical trial to test the paclitaxel - fostamatinib combination therapy in patients with recurrent advanced ovarian cCancer Cell, Johns Hopkins researchers say they are planning a phase I clinical trial to test the paclitaxel - fostamatinib combination therapy in patients with recurrent advanced ovarian cancercancer.

Chemotherapy drugs designed to kill tumors may actually encourage ovarian cancer by stimulating the growth of cells that give rise to the malignancy, a new study finds.

«Because there is currently no reliable screening available for ovarian cancer, most cases are diagnosed at advanced stages,» said the study's author, Bo (Bonnie) Qin, PhD, a postdoctoral associate at Rutgers Cancer Institute of New Jcancer, most cases are diagnosed at advanced stages,» said the study's author, Bo (Bonnie) Qin, PhD, a postdoctoral associate at Rutgers Cancer Institute of New JCancer Institute of New Jersey.

But this situation may soon change if researchers can extend the promise of a recent study, in which scientists detected ovarian cancer from blood samples with near 100 percent accuracy.

The study published in Cancer Cell shows that exosomes from tumor cells of breast cancer (and other tumor types such as ovarian and endometrial) are different in size and composition than those of healthy Cancer Cell shows that exosomes from tumor cells of breast cancer (and other tumor types such as ovarian and endometrial) are different in size and composition than those of healthy cancer (and other tumor types such as ovarian and endometrial) are different in size and composition than those of healthy cells.

To identify the relevant mutations the scientists analyzed the blood samples of 1,858 men from three independent cohorts in Europe and North America: the Swiss arm of the European Randomized Study for Prostate Cancer Screening, the large American Screening trial, Prostate, Lung, Colorectal, and Ovarian (PLCO), Princess Margaret Cancer Centre (University Health Network) and Mount Sinai Hospital (Sinai Health System) in Toronto.

Qin said that among all African - American women in the study, those with the highest adherence to an AHEI - 2010 diet were 34 percent less likely to be diagnosed with ovarian cancer than women with the lowest AHEI - 2010 adherence.

In order to assess whether an improved diet could reduce the risk of ovarian cancer in African - American women, Qin analyzed the diets of 415 women with ovarian cancer and 629 control patients, using data from the African - American Cancer Epidemiology Study, a population - based case - control study of ovarian cancer in African - American women in 11 sites in the United Scancer in African - American women, Qin analyzed the diets of 415 women with ovarian cancer and 629 control patients, using data from the African - American Cancer Epidemiology Study, a population - based case - control study of ovarian cancer in African - American women in 11 sites in the United Scancer and 629 control patients, using data from the African - American Cancer Epidemiology Study, a population - based case - control study of ovarian cancer in African - American women in 11 sites in the United SCancer Epidemiology Study, a population - based case - control study of ovarian cancer in African - American women in 11 sites in the United StStudy, a population - based case - control study of ovarian cancer in African - American women in 11 sites in the United Ststudy of ovarian cancer in African - American women in 11 sites in the United Scancer in African - American women in 11 sites in the United States.

But Weidhaas and Slack's studies showed how the KRAS - variant increases a woman's risk of ovarian cancer — more than 27 percent of women with this type of cancer carried the variant.

Martin Matzuk, an endocrinologist at Baylor College of Medicine in Houston, began studying FSH for another reason: to investigate the hormone's role in ovarian cancer.

Another study, conducted by Barbara Weber and her colleagues at the University of Pennsylvania, screened 263 breast cancer patients for BRCA1 mutations and asked them about their family history of breast and ovarian cancers.

Razqallah Hakem, a cancer biologist at the University of Toronto in Ontario, and his colleagues normally study a tumor suppressor called BRCA1, variants of which put women at high risk of breast and ovarian cancer.

Funding for the study was provided by the National Institutes of Health (P50 CA083638, R21 CA156224, 5P30 CA016520 - 36), the Marcus Foundation, the Ovarian Cancer Immunotherapy Initiative, the Ludwig Institute for Cancer Research at the University of Lausanne, and the Ovacure Foundation.

The study, which compared each model's success in Caucasian women with those of Asian descent (Chinese, Japanese, Filipino, Korean and Vietnamese), also raised important questions about the effect of race on cancer development: When Caucasian and Asian patients with similar family histories of breast and ovarian cancer were compared, the Asian women had higher rates of genetic mutation, although the rates of these cancers for Asians have traditionally been lower.

«Women who carry a mutation in BRCA genes have an increased risk of developing breast and ovarian cancer,» Kristy A. Brown, Ph.D., study principal investigator, said.

A study involving Ottawa and Taiwan researchers, published in the journal Proceedings of the National Academy of Sciences (PNAS), provides new insight into why ovarian cancer is often resistant to chemotherapy, as well as a potential way to improve its diagnosis and treatment.

«This study provided encouraging preliminary results for the use of RT in women with ovarian cancer.»

And that's when ovarian cancer becomes deadly,» says study author J. Rebecca Liu, M.D., associate professor of obstetrics and gynecology at the University of Michigan.

The study evaluated 56 patients with ovarian clear cell adenocarcinoma (CCA), an aggressive form of ovarian cancer that is more likely to be resistant to chemotherapy and to have a poorer prognosis than other forms of this disease.

The team's recent study in mice has found that the treatment reduced the mass of ovarian cancer tumors and was more effective at suppressing tumor growth than chemotherapy.

TRINOVA - 2 is evaluating pegylated liposomal doxorubicin in combination with either placebo or trebananib in previously treated patients with ovarian cancer while TRINOVA - 3, also known as ENGOT - Ov2 and Gynecologic Oncology Group — 3001, is studying the use of trebananib in front - line treatment adding it to carboplatin / paclitaxel.

«This study also adds greater understanding of tumor - infiltrating lymphocytes and their influence on the causes and progression of ovarian cancer.

Heeke says the study would be open to people whose tumors have evidence of HRD like those found in this study, which includes bladder, breast, cervix, liver and bile duct, colorectal, endometrial, gastric / esophageal, head & neck, kidney, neuroendocrine, lung, ovarian, pancreas, prostate, sarcoma, and thyroid cancers, as well as gastrointestinal stromal tumors, glioma, melanoma and unknown primary cancers.

Diamond is also quick to point out that while the current study shows that COXEN could have been used to predict the most useful drug in many of these cases of advanced ovarian cancer, the actual use of the model will be possible only after validation with a prospective clinical trial.

This is the largest study of its kind to use new technology to comprehensively investigate the inherited basis of ovarian cancer.

«This study supports the idea that we could test ovarian cancer tumors and say they're more likely to respond to one or the other drugs,» Diamond says.

The role of weight in ovarian - cancer risk emerges from an analysis of data on some 68,000 women participating in one of three major ongoing investigations: the New York (City) University Women's Health Study, the Northern Sweden Health and Disease Study in Umea, and the Diet in the Etiology of Breast Cancer Study in Milan, cancer risk emerges from an analysis of data on some 68,000 women participating in one of three major ongoing investigations: the New York (City) University Women's Health Study, the Northern Sweden Health and Disease Study in Umea, and the Diet in the Etiology of Breast Cancer Study in Milan, Cancer Study in Milan, Italy.

Acknowledging that «this is not a big study, in terms of the overall number of cases, for ovarian cancer it's a very big study,» explains Annekatrin Lukanova of the International Agency for Cancer Research in Lyon, Fcancer it's a very big study,» explains Annekatrin Lukanova of the International Agency for Cancer Research in Lyon, FCancer Research in Lyon, France.

Where mutations occur in two important cancer genes can affect a woman's risk of breast or ovarian cancer, a study of thousands of women shows.

To capture uncommon genetic variants, the study used an exome genotyping array to genotype 7,060 epithelial ovarian cancer (EOC) cases and 6,712 cancer - free women from the Ovarian Cancer Association Consovarian cancer (EOC) cases and 6,712 cancer - free women from the Ovarian Cancer Association Consocancer (EOC) cases and 6,712 cancer - free women from the Ovarian Cancer Association Consocancer - free women from the Ovarian Cancer Association ConsOvarian Cancer Association ConsoCancer Association Consortium.